A Study to Evaluate the Efficacy & Safety of Gantenerumab in Participants

See also
Status	Clinical Trial	Phase
Completed	`NCT02409082` - Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures	N/A
Terminated	`NCT02565511` - A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease	Phase 2/Phase 3
Completed	`NCT01993836` - Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care	Phase 4
Terminated	`NCT05097131` - An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Completed	`NCT00448799` - Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls	Phase 1
Recruiting	`NCT04639050` - Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2
Terminated	`NCT06424236` - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation	Phase 2/Phase 3
Active, not recruiting	`NCT05891496` - A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	Phase 3
Terminated	`NCT01723488` - A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808	Phase 0
Terminated	`NCT01733355` - A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807	Phase 0
Completed	`NCT00911690` - Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders	N/A
Recruiting	`NCT01479855` - Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type	N/A
Completed	`NCT01469351` - Identifying Potential Effects of Liraglutide on Degenerative Changes	N/A
Completed	`NCT00439010` - Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects	Phase 1
Recruiting	`NCT05269394` - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	Phase 2/Phase 3
Recruiting	`NCT01760005` - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001	Phase 2/Phase 3
Completed	`NCT04623242` - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.	Phase 2/Phase 3
Suspended	`NCT05552157` - A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/Phase 3
Completed	`NCT04023994` - A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants	Phase 1
Terminated	`NCT03131453` - A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease	Phase 2/Phase 3

NCT number	NCT05256134
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Terminated
Phase	Phase 3
Start date	April 19, 2022
Completion date	March 10, 2023

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) — SKYLINE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms